Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ARTEMIS: Ixo-vec vs Aflibercept in Neovascular Age-Related Macular Degeneration
NCT06856577Phase 3Active, not recruiting
- Sponsor
- Adverum Biotechnologies
- Start
- Feb 2025
- Primary completion
- Dec 2026
- Modality
- Gene Editing, Gene Silencing, AAV Vectors
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ixoberogene soroparvovec in neovascular age-related macular degeneration (NVAMD) (2 arms), sponsored by Adverum Biotechnologies. Primary endpoint: Mean change from Baseline in Best-Corrected Visual Acuity at 56 weeks. Started Feb 2025; status: active, not recruiting.
02
Drugs
ixoberogene soroparvovec
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT06856577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06856577.